Interlaboratory comparison of K-ras testing by real-time PCR and RFLP in colorectal cancer samples

Diagnostic Molecular Pathology

Volumn 20, Issue 2, 2011, Pages 90-93

  Lanthaler, Andrea Judith ^a   Spizzo, Gilbert ^a   Mitterer, Manfred ^a   Mian, Christine ^b   Mazzoleni, Guido ^b  

^a FRANZ TAPPEINER HOSPITAL   (Italy)

^b Regional Hospital   (Italy)

Author keywords

K ras; real time PCR; RFLP

Indexed keywords

K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATHOLOGY, MOLECULAR; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 79958053023     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31820e5f9a     Document Type: Article

References (14)

1. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975 to 2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100: 1672-1694.
2. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18: 1688-1694
3. Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18:1695-1698.
4. Welch S, Spithoff K, Rumble RB, et al. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010;21:1152-1162.
5. Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol. 2010;17:1168-1176.
6. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumor response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with Cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38-47.
7. Giusti RM, Cohen MH, Keegan P, et al. FDA review of a Panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. Oncologist. 2009;14:284-290.
8. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-2096.
9. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from Cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
10. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-1417.
11. Saif MW, Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol. 2009;7:45-53, 64.
12. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008;453:417-431.
13. Beau-Faller M, Legrain M, Voegeli AC, et al. Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer. 2009;100: 985-992.
14. Weichert W, Schewe C, Lehmann A, et al. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn. 2010; 12:35-42.